

References

I-296

1. Blau N, Pearson TS, Kurian MA, et al. Aromatic L-Amino Acid Decarboxylase Deficiency. 2023
Oct 12. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.
2. U.S. Food and Drug Administration. FDA approves first gene therapy treatment for aromatic Lamino acid decarboxylase deficiency. [Press release]. Silver Spring, MD: U.S. Food and Drug Administration; November 14, 2024. Available at: [<https://www.fda.gov/news-events/pressannouncements/fda-approves-first-gene-therapy-treatment-aromatic-l-amino-acid-decarboxylasedeficiency>].
3. A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocogene Exuparvovec to Pediatric Participants. ClinicalTrials.gov identifier: NCT04903288. Updated November 13, 2024. Accessed December 27, 2024. <https://clinicaltrials.gov/study/NCT04903288?term=NCT04903288&rank=1>
4. Kebilidi™ (eladocogene exuparvovec-tneq), suspension, for intraputaminial infusion [package insert]. PTC Therapeutics, Inc. Warren, NJ. Issued 11/2024.
5. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Eladocogene Exuparvovec.
6. Micromedex DrugDex Compendium®. 2024. Eladocogene Exuparvovec-tneq